Cagrilintide
Cagrilintide is a long-acting, lab-made version of amylin, the hormone the pancreas releases with insulin to signal fullness, developed by Novo Nordisk as a once-weekly injection. It has been studied for weight loss in people through Phase 3 trials and remains investigational.
At a glance
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 2.4 mg per Peptide Dosing Protocols. See the source
How much to draw
Full calculator →Opened on 2.4 mg, the figure Peptide Dosing Protocols reports for Cagrilintide. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Cagrilintide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 2.4 mg/week · Low: 0.25 mg/week · High: 4.5 mg/week | once weekly16 weeks | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: About 159 to 195 hours(~7 to 8 days). Cagrilintide is dosed starting at 0.25 mg once weekly, escalating to 2.4 mg weekly. |
- once weekly16 weeks
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: About 159 to 195 hours(~7 to 8 days). Cagrilintide is dosed starting at 0.25 mg once weekly, escalating to 2.4 mg weekly.
- BAC water added per vial; concentration depends on volume chosen.
We have not published an audit on Cagrilintide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Cagrilintide is designed to make people feel full sooner, stay full longer and empty the stomach more slowly. Researchers link this to its action on amylin and calcitonin receptors, and a fatty acid attachment gives it a half-life of about 159 to 195 hours. In the Phase 3 REDEFINE 1 trial it produced 11.8% mean weight loss versus 2.3% with placebo over 68 weeks. Multi-year outcome data is still maturing, and the REDEFINE 3 cardiovascular trial has not yet reported.
It is a long-acting analogue of amylin, the hormone the pancreas releases with insulin to signal fullness after eating. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: most effects in trials were in the gut and rose with dose. In a Phase 2 trial of 706 people, the 4.5 mg weekly group reported nausea 47%, injection-site reactions 43%, constipation 21%, fatigue 20% and vomiting 8%. About 4% across dose groups stopped because of adverse events. One participant at 4.5 mg developed gallstones, and 46-73% developed antibodies to the drug by week 26, with no clear effect on efficacy or safety. A dedicated heart-rhythm study found no clinically relevant QTc prolongation.
Not ruled out: pancreatitis, gallbladder disease, severe low blood sugar (mainly with insulin or sulfonylureas) and kidney injury from dehydration after severe nausea or vomiting. These appear in related amylin or GLP-1 drug data but have not been confirmed in cagrilintide trials. Long-term cardiovascular outcomes are still being evaluated in REDEFINE 3.
Who should avoid it
People with type 1 diabetes: excluded from the Phase 3 trials.
People with a history of pancreatitis: excluded from the Phase 3 trials.
People with severe gastroparesis: excluded from the Phase 3 trials.
People who are pregnant or breastfeeding: excluded from the Phase 3 trials.
People with recent major cardiovascular events: excluded from the Phase 3 trials.
People with active cancer: excluded from the Phase 3 trials.
People with severe kidney or liver impairment: excluded from the Phase 3 trials.
People with a personal or family history of medullary thyroid carcinoma or MEN2: excluded, as a GLP-1 class caution that may extend to combination products.
People on oral medicines with narrow dosing windows, such as warfarin, levothyroxine, oral contraceptives and some seizure medicines: it slows stomach emptying, which can change how these are absorbed.
People on insulin or other glucose-lowering drugs: doses may need adjusting to lower the risk of low blood sugar.
What gets monitored
GI tolerance, body weight, blood pressure, fasting glucose, and HbA1c if T2D. (reported by Peptide Dosing Protocols)
Common questions
What is the starting dose of cagrilintide?
Reported amounts and schedules for Cagrilintide differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is cagrilintide's half-life?
Its plasma half-life is reported as about 159-195 hours, or roughly 6.6-8.1 days. This long half-life is the basis for once-weekly dosing.
How much weight loss is reported with cagrilintide?
In the Phase 3 REDEFINE 1 trial, cagrilintide alone at 2.4 mg produced 11.8% mean weight loss versus 2.3% with placebo over 68 weeks. In the 26-week Phase 2 trial, the 4.5 mg group lost 10.8% and the 2.4 mg group lost 9.7%.
How do you reconstitute cagrilintide?
Sources describe mixing it with bacteriostatic water, added slowly down the inside wall of the vial.
Open the reconstitution calculator →Is cagrilintide FDA-approved?
No. As of June 2026, cagrilintide is not FDA-approved in any form. It remains investigational.
What are the most common cagrilintide side effects?
Most are in the gut and rise with dose. In the Phase 2 trial, nausea was reported by 47% and injection-site reactions by 43% at the 4.5 mg weekly dose. They typically peak during dose escalation and ease on a stable dose.
How does cagrilintide compare to semaglutide and tirzepatide?
Cagrilintide acts on amylin and calcitonin receptors, while semaglutide acts on the GLP-1 receptor. In a Phase 1b trial, cagrilintide plus semaglutide produced 17.1% weight loss versus 9.8% with semaglutide alone. In the open-label REDEFINE 4 trial, CagriSema reached 23.0% at 84 weeks versus 25.5% for tirzepatide 15 mg, and noninferiority was not met.
What vial sizes are available for cagrilintide?
Most research suppliers list 5 mg and 10 mg freeze-dried (lyophilized) vials.
Sources
- 01Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine (2025)
- 02Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). New England Journal of Medicine (2025)
- 03Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a Phase 2 trial. The Lancet (2021)
- 04Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide for weight management: a Phase 1b trial. The Lancet (2021)
- 05Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a Phase 2 trial. The Lancet (2023)
- 06Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry (2021)
- 07Fletcher MM, Belousoff MJ, Harikumar KG, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications (2025)
- 08Dehestani B, Stratford NR, le Roux CW. Amylin as a Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome (2021)
- 09Dutta D, Nagendra L, Harish BG, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (CagriSema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian Journal of Endocrinology and Metabolism (2024)
- 10D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review (2024)
- 11Novo Nordisk (press release). CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM. PR Newswire (2025)
- 12Novo Nordisk (press release). Novo Nordisk files for FDA approval of CagriSema (December 18, 2025). PR Newswire (2025)
- 13ClinicalTrials.gov. REDEFINE 1 (NCT05567796), REDEFINE 2 (NCT05394519), REDEFINE 3 (NCT05669755), REDEFINE 4 (NCT06131437), REDEFINE 11 (NCT07011667), REIMAGINE 2 (NCT06065540). U.S. National Library of Medicine (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.